Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot P02766: Variant p.Leu75Gln

Transthyretin
Gene: TTR
Feedback?
Variant information Variant position: help 75 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change: help From Leucine (L) to Glutamine (Q) at position 75 (L75Q, p.Leu75Gln). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Change from medium size and hydrophobic (L) to medium size and polar (Q) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help -2 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description: help In AMYLD1. Any additional useful information about the variant.


Sequence information Variant position: help 75 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 147 The length of the canonical sequence.
Location on the sequence: help KAADDTWEPFASGKTSESGE L HGLTTEEEFVEGIYKVEIDT The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences.
Human                         KAADDTWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDT

Chimpanzee                    KAADETWEPFASGKTSESGELHGLTTEEEFVEGIYKVEIDT

Mouse                         KTSEGSWEPFASGKTAESGELHGLTTDEKFVEGVYRVELDT

Rat                           KTADGSWEPFASGKTAESGELHGLTTDEKFTEGVYRVELDT

Pig                           KAADGTWEPFALGKTSEFGELHGLTTDEKFVEGIYKVELDT

Bovine                        KAADETWEPFASGKTSESGELHGLTTEDKFVEGLYKVELDT

Rabbit                        KAADETWEPFASGKTSKTGELHGLTTSEKFVEGVYKVELDT

Sheep                         KAADETWEPFASGKTSDSGELHGLTTEDKFVEGLYKVELDT

Chicken                       KAADGTWQDFATGKTTEFGEIHELTTEEQFVEGVYRVEFDT

Xenopus laevis                QTESGKWEQITSGKTTELGEIHNLTTDEQFTEGVYKIEFAT

Xenopus tropicalis            NT-EGNWELISSGKTTELGEIHNIITDEQFTEGVYKIEFAT

Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 21 – 147 Transthyretin
Binding site 74 – 74
Modified residue 62 – 62 4-carboxyglutamate; in a patient with Moyamoya disease
Modified residue 72 – 72 Phosphoserine
Beta strand 73 – 75



Literature citations
A new transthyretin variant Leu55Gln in a patient with systemic amyloidosis.
Yazaki M.; Varga J.; Dyck P.J.; Benson M.D.;
Amyloid 9:268-271(2002)
Cited for: VARIANT AMYLD1 GLN-75;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.